Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis

Zheng Fu, Peter C. Smith, Lizhi Zhang, Mark A. Rubin, Rodney L. Dunn, Zhi Yao, Eva T. Keller

Research output: Contribution to journalArticle

315 Citations (Scopus)

Abstract

Background: Raf kinase inhibitor protein (RKIP), an inhibitor of Raf-mediated activation of mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK), is expressed at lower levels in human C4-2B metastatic prostate cancer cells than in the parental non-metastatic LNCaP prostate cancer cells from which they were derived. We examined whether RKIP functions as a suppressor of metastasis. Methods: Immunohistochemistry was used to detect RKIP expression in clinical samples of primary prostate cancer and prostate cancer metastases. LNCaP and C4-2B cells were stably transfected with plasmids that constitutively expressed antisense and sense RKIP cDNA, respectively, or with empty vector. Assays of cell proliferation, soft-agar colony formation, and in vitro cell invasion were used to examine the malignant phenotypes of the transfected cells. An orthotopic murine model was used to examine the effect of expressing RKIP in C4-2B cells on the development of spontaneous metastasis. Results: Clinical samples of primary prostate cancer had detectable RKIP expression, whereas clinical samples of prostate cancer metastases did not. There were no differences in the in vitro proliferation rate or colony-forming ability between the control vector-transfected and sense RKIP vector-transfected C4-2B cells or between the control vector-transfected and the antisense RKIP vector-transfected LNCaP cells. Overexpression of RKIP in C4-2B cells was associated with decreased in vitro cell invasion, decreased development of lung metastases in vivo, and decreased vascular invasion in the primary tumor but did not affect primary tumor growth in mice. Conclusions: RKIP does not influence the tumorigenic properties of human prostate cancer cells. It appears to be a novel and clinically relevant suppressor of metastasis that may function by decreasing vascular invasion.

Original languageEnglish (US)
Pages (from-to)878-889
Number of pages12
JournalJournal of the National Cancer Institute
Volume95
Issue number12
StatePublished - Jun 18 2003
Externally publishedYes

Fingerprint

Phosphatidylethanolamine Binding Protein
Prostatic Neoplasms
Neoplasm Metastasis
Blood Vessels
MAP Kinase Kinase Kinases
Extracellular Signal-Regulated MAP Kinases
Mitogens
Agar

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fu, Z., Smith, P. C., Zhang, L., Rubin, M. A., Dunn, R. L., Yao, Z., & Keller, E. T. (2003). Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. Journal of the National Cancer Institute, 95(12), 878-889.

Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. / Fu, Zheng; Smith, Peter C.; Zhang, Lizhi; Rubin, Mark A.; Dunn, Rodney L.; Yao, Zhi; Keller, Eva T.

In: Journal of the National Cancer Institute, Vol. 95, No. 12, 18.06.2003, p. 878-889.

Research output: Contribution to journalArticle

Fu, Z, Smith, PC, Zhang, L, Rubin, MA, Dunn, RL, Yao, Z & Keller, ET 2003, 'Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis', Journal of the National Cancer Institute, vol. 95, no. 12, pp. 878-889.
Fu, Zheng ; Smith, Peter C. ; Zhang, Lizhi ; Rubin, Mark A. ; Dunn, Rodney L. ; Yao, Zhi ; Keller, Eva T. / Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. In: Journal of the National Cancer Institute. 2003 ; Vol. 95, No. 12. pp. 878-889.
@article{de82092b8399408483a2d69ece90d977,
title = "Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis",
abstract = "Background: Raf kinase inhibitor protein (RKIP), an inhibitor of Raf-mediated activation of mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK), is expressed at lower levels in human C4-2B metastatic prostate cancer cells than in the parental non-metastatic LNCaP prostate cancer cells from which they were derived. We examined whether RKIP functions as a suppressor of metastasis. Methods: Immunohistochemistry was used to detect RKIP expression in clinical samples of primary prostate cancer and prostate cancer metastases. LNCaP and C4-2B cells were stably transfected with plasmids that constitutively expressed antisense and sense RKIP cDNA, respectively, or with empty vector. Assays of cell proliferation, soft-agar colony formation, and in vitro cell invasion were used to examine the malignant phenotypes of the transfected cells. An orthotopic murine model was used to examine the effect of expressing RKIP in C4-2B cells on the development of spontaneous metastasis. Results: Clinical samples of primary prostate cancer had detectable RKIP expression, whereas clinical samples of prostate cancer metastases did not. There were no differences in the in vitro proliferation rate or colony-forming ability between the control vector-transfected and sense RKIP vector-transfected C4-2B cells or between the control vector-transfected and the antisense RKIP vector-transfected LNCaP cells. Overexpression of RKIP in C4-2B cells was associated with decreased in vitro cell invasion, decreased development of lung metastases in vivo, and decreased vascular invasion in the primary tumor but did not affect primary tumor growth in mice. Conclusions: RKIP does not influence the tumorigenic properties of human prostate cancer cells. It appears to be a novel and clinically relevant suppressor of metastasis that may function by decreasing vascular invasion.",
author = "Zheng Fu and Smith, {Peter C.} and Lizhi Zhang and Rubin, {Mark A.} and Dunn, {Rodney L.} and Zhi Yao and Keller, {Eva T.}",
year = "2003",
month = "6",
day = "18",
language = "English (US)",
volume = "95",
pages = "878--889",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis

AU - Fu, Zheng

AU - Smith, Peter C.

AU - Zhang, Lizhi

AU - Rubin, Mark A.

AU - Dunn, Rodney L.

AU - Yao, Zhi

AU - Keller, Eva T.

PY - 2003/6/18

Y1 - 2003/6/18

N2 - Background: Raf kinase inhibitor protein (RKIP), an inhibitor of Raf-mediated activation of mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK), is expressed at lower levels in human C4-2B metastatic prostate cancer cells than in the parental non-metastatic LNCaP prostate cancer cells from which they were derived. We examined whether RKIP functions as a suppressor of metastasis. Methods: Immunohistochemistry was used to detect RKIP expression in clinical samples of primary prostate cancer and prostate cancer metastases. LNCaP and C4-2B cells were stably transfected with plasmids that constitutively expressed antisense and sense RKIP cDNA, respectively, or with empty vector. Assays of cell proliferation, soft-agar colony formation, and in vitro cell invasion were used to examine the malignant phenotypes of the transfected cells. An orthotopic murine model was used to examine the effect of expressing RKIP in C4-2B cells on the development of spontaneous metastasis. Results: Clinical samples of primary prostate cancer had detectable RKIP expression, whereas clinical samples of prostate cancer metastases did not. There were no differences in the in vitro proliferation rate or colony-forming ability between the control vector-transfected and sense RKIP vector-transfected C4-2B cells or between the control vector-transfected and the antisense RKIP vector-transfected LNCaP cells. Overexpression of RKIP in C4-2B cells was associated with decreased in vitro cell invasion, decreased development of lung metastases in vivo, and decreased vascular invasion in the primary tumor but did not affect primary tumor growth in mice. Conclusions: RKIP does not influence the tumorigenic properties of human prostate cancer cells. It appears to be a novel and clinically relevant suppressor of metastasis that may function by decreasing vascular invasion.

AB - Background: Raf kinase inhibitor protein (RKIP), an inhibitor of Raf-mediated activation of mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK), is expressed at lower levels in human C4-2B metastatic prostate cancer cells than in the parental non-metastatic LNCaP prostate cancer cells from which they were derived. We examined whether RKIP functions as a suppressor of metastasis. Methods: Immunohistochemistry was used to detect RKIP expression in clinical samples of primary prostate cancer and prostate cancer metastases. LNCaP and C4-2B cells were stably transfected with plasmids that constitutively expressed antisense and sense RKIP cDNA, respectively, or with empty vector. Assays of cell proliferation, soft-agar colony formation, and in vitro cell invasion were used to examine the malignant phenotypes of the transfected cells. An orthotopic murine model was used to examine the effect of expressing RKIP in C4-2B cells on the development of spontaneous metastasis. Results: Clinical samples of primary prostate cancer had detectable RKIP expression, whereas clinical samples of prostate cancer metastases did not. There were no differences in the in vitro proliferation rate or colony-forming ability between the control vector-transfected and sense RKIP vector-transfected C4-2B cells or between the control vector-transfected and the antisense RKIP vector-transfected LNCaP cells. Overexpression of RKIP in C4-2B cells was associated with decreased in vitro cell invasion, decreased development of lung metastases in vivo, and decreased vascular invasion in the primary tumor but did not affect primary tumor growth in mice. Conclusions: RKIP does not influence the tumorigenic properties of human prostate cancer cells. It appears to be a novel and clinically relevant suppressor of metastasis that may function by decreasing vascular invasion.

UR - http://www.scopus.com/inward/record.url?scp=0038275924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038275924&partnerID=8YFLogxK

M3 - Article

VL - 95

SP - 878

EP - 889

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

ER -